ArticleJournal of gastrointestinal cancer2011
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Article in Journal of gastrointestinal cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.World journal of gastroenterology · 2015Pooled it
- PathSynergy: a deep learning model for predicting drug synergy in liver cancer.Briefings in bioinformatics · 2025Article
- Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?World journal of transplantation · 2020Review
- Is the era of sorafenib over? A review of the literature.Therapeutic advances in medical oncology · 2020Review
- Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy.OncoTargets and therapy · 2019Article
- Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.World journal of gastroenterology · 2015Article
- Liver transplantation for advanced hepatocellular carcinoma: how far can we go?Hepatic oncology · 2015Review
- Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.BMJ case reports · 2014Article
- Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Liver cancer · 2012Review
- Late recurrence of hepatocellular carcinoma after liver transplantation.World journal of surgery · 2011Article
- Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.Medical molecular morphology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo standard therapies have been established for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation. DISCUSSION: Sirolimus is a mTOR inhibitor which has been used as an immunosuppressive medication in patients who are at high risk of tumor reoccurrence after liver transplantation. Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC. However the role of sorafenib in patients with HCC reoccurrence after liver transplantation is unclear.
resultsCombination of sirolimus and sorafenib appears to have synergistic effect when treating HCC in preclinical settings. We report a case of a post-liver transplant patient treated with sorafenib and sirolimus for hepatic HCC recurrence who exhibited complete radiologic response after 5A months of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.